PacBio PACB recently announced a key distribution agreement with Haorui Gene, a globally recognized leader in blood typing ...

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: ...

The reliance on licensed technology from CUHK may raise concerns about PacBio's ability to innovate independently and maintain a competitive edge in the rapidly evolving genomic sequencing market.

Under the terms of the agreement, Haorui Gene will distribute PacBio’s Vega platform throughout China, which, together with other products offered by Haorui Gene, will deliver end-to-end support for ...

GutID utilizes PacBio's HiFi sequencing technology, known for its high accuracy, enhancing the reliability of gut microbiome testing. The test provides comprehensive, actionable insights into gut ...

The study demonstrates the impact of PacBio’s HiFi long-read sequencing technology in identifying genetic causes of rare diseases, illustrating the feasibility of potentially replacing multiple ...

(Reuters) - Gene-sequencing company Pacific BioSciences ... genomes per year for less than $1,000 per genome. PacBio said its trademark HiFi technology – used for large studies in human genetics ...

This premium ratio may be caused by PacBio’s relative positioning in the genomics sequencing market, where their exclusive technology and quality solutions could suffice for an increased price.

This initiative will leverage PacBio's advanced sequencing technology to generate genetic insights that can guide future research, prevention, and treatment efforts. Vaibhav Narayan, Executive ...

researchers utilized the PacBio Revio platform, a long-read sequencing technology, to pinpoint the diagnosis of RFX3 haploinsufficiency syndrome in an adolescent with autism spectrum disorder ...